Get the Stockscreener App
65.46
2.98%
-2.01
After Hours:
66.00
0.54
+0.82%
Guardant Health Inc stock is traded at $65.46, with a volume of 1.61M.
It is down -2.98% in the last 24 hours and up +14.46% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$67.47
Open:
$66.95
24h Volume:
1.61M
Relative Volume:
0.64
Market Cap:
$8.16B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-15.44
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+1.93%
1M Performance:
+14.46%
6M Performance:
+45.56%
1Y Performance:
+216.54%
1-Day Range:
$64.00
$67.09
1-Week Range:
$61.00
$68.23
52-Week Range:
$20.14
$68.23
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
65.46 | 8.41B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
538.92 | 202.69B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
209.06 | 151.03B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
635.40 | 50.99B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
141.92 | 40.00B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
204.55 | 34.98B | 15.70B | 1.24B | 2.01B | 6.9036 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Why Guardant Health Inc. stock is recommended by analystsPortfolio Risk Summary & Growth Focused Stock Reports - newser.com
Is Guardant Health Inc. building a consolidation baseQuarterly Profit Summary & Real-Time Buy Zone Alerts - newser.com
Guardant Health stock hits 52-week high at 68.01 USD - Investing.com
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025 - 01net
Guardant Health And Collaborators To Present New Data Across The Cancer Care Continuum At Esmo 2025 - TradingView
What institutional flow reveals about Guardant Health Inc.July 2025 WrapUp & Daily Volume Surge Signals - newser.com
How to use Fibonacci retracement on Guardant Health Inc.July 2025 Opening Moves & Safe Entry Point Alerts - newser.com
Guardant Health files lawsuit against Natera for stealing trade secrets - MSN
How to track smart money flows in Guardant Health Inc.Stock Surge & Free Technical Confirmation Trade Alerts - newser.com
Can Guardant Health Inc. stock deliver consistent earnings growthTrade Entry Summary & High Accuracy Trade Alerts - newser.com
Guardant Health: Hold Rating Ahead Of Q3 Results On Valuation And Execution Risk (GH) - Seeking Alpha
Guardant Health, Inc. (GH) Stock Analysis: A Growth Powerhouse with a 6.81% Upside Potential - DirectorsTalk Interviews
What analysts say about Guardant Health Inc stockRisk-Reward Ratio Analysis & Best Stocks For Explosive Growth - earlytimes.in
Guardant Health, Inc. (NASDAQ:GH) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Using Ichimoku Cloud for Guardant Health Inc. technicals2025 Retail Activity & High Return Stock Watch Alerts - newser.com
Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025 - FinancialContent
CustomerThink - CustomerThink
Quantitative breakdown of Guardant Health Inc. recent movePortfolio Update Report & Free Expert Verified Stock Movement Alerts - newser.com
Why Guardant Health Inc. (5GH) stock stays on top picksOptions Play & AI Powered Market Entry Strategies - newser.com
Pattern recognition hints at Guardant Health Inc. upsideTake Profit & Weekly High Conviction Trade Ideas - newser.com
Abel Hall LLC Invests $202,000 in Guardant Health, Inc. $GH - MarketBeat
Published on: 2025-10-09 03:21:22 - newser.com
Guardant Health's (GH) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
What drives Guardant Health Inc 5GH stock priceAnalyst Downgrades & Market Volatility Strategies - earlytimes.in
Evercore ISI Group Raises Price Target for Guardant Health (GH) to $68 | GH Stock News - GuruFocus
Evercore ISI Raises Guardant Health (NASDAQ:GH) Price Target to $68.00 - MarketBeat
Liquid Biopsy for Early Cancer Detection and Monitoring - GlobeNewswire
Liquid Biopsy for Early Cancer Detection and Monitoring Market Report 2025-2033, with Profiles of GRAIL, AnchorDx, Burning Rock Biotech, Genecast, Guardant Health, Elypta, Freenome, and Oncimmune - Yahoo Finance
Is Guardant Health Inc. (5GH) stock dividend growth reliableTrade Performance Summary & AI Forecast for Swing Trade Picks - newser.com
Visualizing Guardant Health Inc. stock with heatmapsCPI Data & Weekly Return Optimization Plans - newser.com
What momentum shifts mean for Guardant Health Inc.Quarterly Market Review & Precise Trade Entry Recommendations - newser.com
Using economic indicators to assess Guardant Health Inc. potentialJuly 2025 Drop Watch & Smart Allocation Stock Reports - newser.com
Guardant Health Inc Stock Analysis and ForecastMarket Liquidity Analysis & Rapid Capital Trading Plans - earlytimes.in
Shareholders in Guardant Health (NASDAQ:GH) Are in the Red If They Invested Three Years Ago - 富途牛牛
Guardant Health gets FDA nod for Guardant360 CDx as a companion diagnostic - MSN
How FDA Approval of Guardant360 CDx as Companion Diagnostic Could Impact Guardant Health (GH) Investors - Yahoo Finance
Is Quest Diagnostics' (DGX) Shield Partnership Transforming Its Role in Preventive Health Innovation? - Yahoo Finance
How to use a screener to detect Guardant Health Inc. breakoutsTrade Risk Report & Smart Money Movement Alerts - newser.com
Comparing Guardant Health Inc. in custom built stock radarsJuly 2025 WrapUp & Entry Point Strategy Guides - newser.com
Risk adjusted return profile for Guardant Health Inc. analyzedMarket Sentiment Report & Daily Momentum Trading Reports - newser.com
Barclays Raises Price Target for Guardant Health (GH) to $70.00 | GH Stock News - GuruFocus
4,782 Shares in Guardant Health, Inc. $GH Purchased by Trivium Point Advisory LLC - MarketBeat
GCC Liquid Biopsy Market Forecast and Company Analysis - GlobeNewswire
GCC Liquid Biopsy Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Bio-Rad, Thermo Fisher Scientific, Johnson & Johnson, Guardant Health, QIAGEN, Sysmex - Yahoo Finance
Sicart Associates LLC Increases Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Unveils Shield V2, Boosts Early Cancer Detection Accuracy - Insider Monkey
What drives Guardant Health Inc stock priceEx-Dividend Date Alerts & Free Take Advantage Of Momentum - earlytimes.in
Stocks making big moves yesterday: Beyond Meat, The Trade Desk, Guardant Health, PayPal, and Tilray - The Globe and Mail
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):